Optimi Health announces entering into a supply agreement with Halucenex Life Sciences Inc that "pertains to the entirety of" Optimi's recently cultivated psilocybe mushrooms.
TSI EDITOR |
2022-05-27
Awakn Life Sciences announces filing a patent application for the treatment of behavioral addictions with ketamine-assisted psychotherapy.
TSI EDITOR |
2022-05-26
Pharmather announces a new development agreement with CCBIO to create a proprietary wearable ketamine delivery solution for mental health.
TSI EDITOR |
2022-05-25
Optimi Health announces the completion of its first crop of psilocybin mushrooms at the company's Princeton, B.C. cultivation facility.
TSI EDITOR |
2022-05-25
Small Pharma issues a corporate update, reporting R&D and IP progress, with ~CAD$40 million in cash as of February 28, 2022.
TSI EDITOR |
2022-05-25
The psychedelic drug industry has suddenly attracted the attention of the most influential "power players" on the planet. It's great news for the industry, but...
TSI EDITOR |
2022-05-24
MindMed announces the appointment of Schond L. Greenway as its new CFO, bringing a wealth of experience in banking and corporate finance.
TSI EDITOR |
2022-05-23
Compass Pathways announces the release of the largest randomized, controlled, double-blind study ever completed on psilocybin-assisted therapy.
TSI EDITOR |
2022-05-23
GH Research reports its Q1 2022 results. Net loss of $5.8 million. Cash position of $270.8 million as of March 31, 2022.
TSI EDITOR |
2022-05-18
Seelos Therapeutics announces receiving its Notice of Allowance from the USPTO for SLS-007 as a method of treatment.
TSI EDITOR |
2022-05-18
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now